Table of Contents

company-logo

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

ImmunityBio Dividend Announcement

• ImmunityBio does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on ImmunityBio dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

ImmunityBio Dividend History

ImmunityBio Dividend Yield

ImmunityBio current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing ImmunityBio stock? Use our calculator to estimate your expected dividend yield:

ImmunityBio Financial Ratios

P/E ratio-5.97
PEG ratio-2.15
P/B ratio-4.71
ROE86.39%
Payout ratio0.00%
Current ratio2.68
Quick ratio2.64
Cash Ratio1.84

ImmunityBio Dividend FAQ

Does ImmunityBio stock pay dividends?
ImmunityBio does not currently pay dividends to its shareholders.
Has ImmunityBio ever paid a dividend?
No, ImmunityBio has no a history of paying dividends to its shareholders. ImmunityBio is not known for its dividend payments.
Why doesn't ImmunityBio pay dividends?
There are several potential reasons why ImmunityBio would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will ImmunityBio ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While ImmunityBio has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is ImmunityBio a dividend aristocrat?
ImmunityBio is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is ImmunityBio a dividend king?
ImmunityBio is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is ImmunityBio a dividend stock?
No, ImmunityBio is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy ImmunityBio stocks?
To buy ImmunityBio you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy ImmunityBio stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.